Clinical trial
Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma
NCT00177554 · University of Pittsburgh, Other · Completed
Key facts
| NCT number | NCT00177554 |
|---|---|
| Title | Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma |
| Official title | Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma |
| Lead sponsor | University of Pittsburgh, Other |
| Collaborators | Biogen Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin Lymphoma |
| Intervention type | Drug |
| Interventions | Chemotherapy and Radioimmunotherapy |
| Enrollment | 60 |
| Start date | Nov 1, 2003 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Sep 15, 2005 |
| Last update posted | May 29, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: